A case of schizophrenia with congenital color vision deficiency: From the perspective of color universal design to promote medication adherence.
color blindness
color universal design
color vision deficiency
medication adherence
schizophrenia
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
01
06
2022
received:
28
03
2022
accepted:
02
06
2022
pubmed:
26
6
2022
medline:
30
9
2022
entrez:
25
6
2022
Statut:
ppublish
Résumé
Color-blindness, or more accurately, color vision deficiency (CVD), which is the inability or decreased ability to distinguish different colors, is one of the commonest visual disorders. Patients with schizophrenia usually have multiple types of visual processing impairments, including color vision impairments. Here, we present a case of schizophrenia with congenital CVD. The patient was aware of his color deficiency since elementary school. We assessed his ability to distinguish medicines based on their color, including those that he had been previously prescribed. Although he could distinguish all of the tablets, he could not distinguish the color of the blister packs, specifically that of the bromazepam 2 mg pack (green) from the 1 mg pack (red). This case suggests that CVD patients might misunderstand the color of medications, which might lead to medication errors, or poor drug adherence. The color universal design principle should be considered when designing tablets and their blister packs, in order to improve medication adherence.
Identifiants
pubmed: 35751444
doi: 10.1002/npr2.12278
pmc: PMC9515716
doi:
Substances chimiques
Bromazepam
X015L14V0O
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
384-386Informations de copyright
© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Références
Schizophr Res. 2019 Feb;204:162-170
pubmed: 30201549
Psychol Med. 1985 Nov;15(4):859-66
pubmed: 4080889
Neuropsychopharmacol Rep. 2022 Sep;42(3):384-386
pubmed: 35751444
Schizophr Res Cogn. 2015 Jun;2(2):46-55
pubmed: 26345525
Ophthalmol Clin North Am. 2003 Jun;16(2):179-203
pubmed: 12809157
Eye (Lond). 2010 May;24(5):747-55
pubmed: 19927164
Int J Psychiatry Clin Pract. 2020 Jun;24(2):193-200
pubmed: 31916882
Nepal Med Coll J. 2010 Jun;12(2):81-3
pubmed: 21222402
J Opt Soc Am A Opt Image Sci Vis. 2012 Mar 1;29(3):313-20
pubmed: 22472762